Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 3/20 | 0.82 |
| ▸ | RAB9A | P51151 | 3/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.81 |
| ▸ | CNR1 | P21554 | 3/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | CNR2 | P34972 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MITF | O75030 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485213 | 0.88 | CNR2 (1.00) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL4251401 | 0.87 | POLB (0.77) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL13870899 | 0.86 | TP53 (0.81) | SMN1; SMN2NPC1RAB9ATP53POLB | |
| SCHEMBL13532180 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL29717171 | 0.84 | CNR2 (0.73) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL4252422 | 0.83 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL27199080 | 0.83 | RAB9A (0.73) | SMN1; SMN2NPC1RAB9ACNR1POLB | |
| SCHEMBL16085566 | 0.81 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL13532206 | 0.81 | TP53 (0.85) | SMN1; SMN2NPC1RAB9ATP53CNR1 | |
| SCHEMBL4250870 | 0.80 | KMT2A (0.81) | SMN1; SMN2NPC1RAB9ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | SMN1; SMN2 155/4885NPC1 869/4885RAB9A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.